What question did this study set out to answer?

The aim is to assess the efficacy and safety of galantamine in treating Alzheimer's disease.

December 9, 2000BMJOpen Access

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates galantamine's effectiveness in improving cognition in mild to moderate Alzheimer's disease, suggesting clinical relevance.

The aim is to assess the efficacy and safety of galantamine in treating Alzheimer's disease.
Randomised, double-blind, parallel group, placebo-controlled trial involving 653 patients.
Patients received escalating doses of galantamine to maintenance doses of 24 or 32 mg over three to four weeks.
Outcome measures included cognitive scores and clinician assessments at six months.
At six months, the lower dose of galantamine improved cognitive scores by 2.9 points (P<0.001) compared to placebo.
Higher dose patients also showed better clinician impressions, with P<0.05 compared to placebo.
Disability assessment scores improved by 3.4 points in the higher dose group (P<0.05).

Wilcock et al. (2000) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial evaluates galantamine's effectiveness in improving cognition in mild to moderate Alzheimer's disease, suggesting clinical relevance.